Recombinant Human APOC2 protein

**Background of Recombinant APOC2 Protein**

Apolipoprotein C-II (APOC2) is a critical component of lipid metabolism, primarily functioning as a coactivator for lipoprotein lipase (LPL), an enzyme responsible for hydrolyzing triglycerides in circulating chylomicrons and very-low-density lipoproteins (VLDL). This process is essential for delivering free fatty acids to peripheral tissues and maintaining plasma lipid homeostasis. Genetic deficiencies in APOC2 lead to hypertriglyceridemia, characterized by severely elevated triglyceride levels, pancreatitis, and increased cardiovascular risk. Traditional therapies for such disorders often focus on dietary management or lipid-lowering agents, but these approaches may not address the root cause in APOC2-deficient patients.

Recombinant APOC2 protein, produced via genetic engineering techniques (e.g., using bacterial or mammalian expression systems), offers a targeted therapeutic strategy. By restoring LPL activation, it enhances triglyceride clearance, potentially mitigating acute and chronic complications of APOC2 deficiency. Beyond hereditary conditions, recombinant APOC2 is also investigated for its role in modulating lipid metabolism in acquired diseases, such as metabolic syndrome and diabetes, where dysfunctional LPL activity contributes to dyslipidemia.

Research further explores its anti-inflammatory and anti-tumor properties, as altered lipid metabolism is linked to cancer progression and immune dysregulation. However, challenges like short plasma half-life and immunogenicity require optimization through protein engineering, such as PEGylation or fusion technologies. Current studies focus on preclinical models and early-phase clinical trials to evaluate efficacy and safety. Overall, recombinant APOC2 represents a promising biologic tool for both therapeutic intervention and mechanistic studies in lipid-related disorders.